The APP Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of 143B human osteosarcoma cells with disruption of the amyloid precursor protein (APP) gene. This heterogeneous pool contains diverse loss-of-function alleles, achieving functional gene knockout without clonal selection. The knockout abolishes APP expression and both amyloidogenic and non-amyloidogenic processing, preventing formation of A?? peptides and the intracellular domain (AICD). This model is optimized for studying APP function in a non-neuronal cancer context.
The 143B cell line is a highly tumorigenic and metastatic osteosarcoma model derived from a primary tumor. As an osteoblast-derived line, it retains invasive and proliferative properties relevant to bone cancer research. 143B cells are widely used to dissect metastasis mechanisms, drug resistance, and signaling pathways. This background offers a rigorous system to evaluate APP??s contributions to cancer cell adhesion, migration, and survival.
APP is a transmembrane protein processed by ??- and ??-secretase complexes (BACE1, PSEN1) to release A?? and AICD. AICD binds Fe65 (APBB1) and Tip60 to regulate transcription of targets like KAI1, GSK3??, p53, and neprilysin. APP interacts with X11, Dab1, JIP1, and extracellular ligands collagen and heparin, and is modulated by Reelin, inflammatory cytokines, and transcription factors (Sp1, AP-1, NF-??B). These link APP to Notch, MAPK/ERK, PI3K/AKT, and adhesion pathways, controlling motility and gene expression.
In 143B cells, APP knockout disrupts A?? production and AICD-mediated transcription, affecting migration and adhesion via collagen/heparin interactions and Fe65/Tip60-dependent gene regulation. The polyclonal pool ensures robust loss of function, minimizing clonal variation while preserving pathway complexity. This model enables dissection of APP??s roles in osteosarcoma proliferation, invasion, and tumorigenesis.
Applications include functional assays for adhesion, migration, and invasion, drug screening for APP modulators (A?? ELISA, luciferase reporters), and AICD-target gene analysis (qPCR, ChIP). The cells support generation of isogenic controls for comparative studies. Standard validation by Western blot, RT-qPCR, and immunofluorescence is recommended. For additional information, contact Ascent Research.
